A Medical Device Daily

Dade Behring (Deerfield, Illinois) reported that it has received FDA clearance for use of its MicroScan Synergies plus Gram-positive panels.

The company said that the new technology used in the panels enables rapid identification of bacteria and same-day test results for detecting certain antibiotic-resistant bacteria that cause serious health threats in a hospital environment. Some of the antibiotic-resistant bacteria that may be identified are: Methicillin-resistant Staphylococcus aureus, Vancomycin-resistant Staphylococcus aureus, and Vancomycin-resistant Enterococcus.

“Dade Behring feels strongly about addressing this global health issue and continues to develop automated microbiology tests that identify the latest antibiotic-resistant bacteria,” said Jim Reid-Anderson, company president/CEO. “By more quickly confirming the diagnosis of an antibiotic-resistant infection, physicians can treat patients and mitigate life-threatening infections from spreading to others in the hospital environment.”

Dade Behring has nearly 60 MicroScan panels of tests, with up-to-date antibiotics including overnight, rapid and specialty products.